Original-clinicalPulmonary vein isolation by duty-cycled bipolar and unipolar radiofrequency energy with a multielectrode ablation catheter
Introduction
Radiofrequency (RF) catheter ablation has become first-line therapy for patients with drug-refractory atrial fibrillation (AF).1, 2 An early ablation strategy consisted of focal ablation of triggers inside the pulmonary veins (PVs).3 To prevent complications of PV stenosis, this method was modified to electrical isolation of the PV by segmental isolation at the ostium.4, 5 Strategies evolved to include wide area encircling of the PV antrum using sophisticated three-dimensional mapping systems that could reconstruct atrial anatomy for guiding ablation and limiting fluoroscopy time.6, 7 In complex cases of persistent or permanent AF, additional ablation lines can be added, or complex fractionated electrograms can be targeted for ablation.8, 9, 10 The evolution in ablation strategies led to increasingly complex and lengthy procedures and the need for high-technology equipment. Intracardiac echocardiography, computed tomography/magnetic resonance imaging (MRI) integration, and robotic steering have been proposed as new tools for facilitating the procedure. However, the availability of imaging, mapping, and steering options has not necessarily led to better outcomes for patients, and a wide range of success rates is reported in the literature.11
Little progress has been made in the development of new ablation catheters. Traditional catheter ablation is performed in a single-tip, point-by-point ablation process. This technique requires a high degree of operator skill and procedures are lengthy, often more than 4 hours. In addition, creating reliable contiguous transmural lesions with a single-point catheter is difficult. Therefore, there is a need for specialized RF ablation catheters specifically designed for AF ablation. Alternative energy sources currently under investigation may offer advantages over conventional unipolar RF ablation. Here we describe a novel technique for isolation of the PVs by ablation using an over-the-wire multielectrode catheter delivering duty-cycled bipolar and unipolar RF energy at relatively low power.12, 13, 14, 15, 16
Section snippets
Patients and procedure
The study consisted of 98 consecutive patients with paroxysmal or persistent AF seen at the St. Antonius Hospital, Nieuwegein, The Netherlands, between April 2007 and June 2008. Patients were referred by outside cardiologists and were eligible for ablation if they had documented evidence of recurring symptomatic AF refractory to two or more antiarrhythmic drugs within the past 6 months. The study was approved by the St. Antonius Hospital review board, and all patients gave informed consent to
Results
The characteristics of the study group are given in Table 1. Among the 98 patients undergoing the ablation procedure, 23 were female. Mean patient age was 59 ± 9 years (range 34–76 years). Slight left atrial enlargement (40–45 mm) was seen in 18% of patients, and mild (less than grade 2) mitral insufficiency was seen in 12% of patients. The number of antiarrhythmic drugs used prior to ablation was 2 ± 1; only eight patients were taking amiodarone at inclusion into the study. In this patient
Discussion
This study reports the first clinical results of a new decapolar catheter that delivers bipolar/unipolar RF energy and can be used for both mapping and ablation of AF, with no need for three-dimensional imaging or remote navigation.
Conclusion
PV isolation by antrum ablation with a circular, multielectrode catheter using duty-cycled bipolar and unipolar RF energy appears to be feasible and safe, with promising efficacy at 6 months. The fluoroscopy and procedural times appear to be shorter than those associated with current AF ablation techniques, without the need for sophisticated mapping and/or steering modalities.
Acknowledgments
We thank Jay Kelley for manuscript preparation and review and Sadaf Soleymani for Figure 3.
References (32)
- et al.
A new approach for catheter ablation of atrial fibrillation: mapping of the electrophysiologic substrate
J Am Coll Cardiol
(2004) - et al.
HRS/EHRA/ECAS Expert Consensus Statement on catheter and surgical ablation of atrial fibrillation: recommendations for personnel, policy, procedures and follow-upA report of the Heart Rhythm Society (HRS) Task Force on catheter and surgical ablation of atrial fibrillation
Heart Rhythm
(2007) - et al.
A new radiofrequency thermal balloon catheter for pulmonary vein isolation
J Am Coll Cardiol
(2001) - et al.
Pulmonary vein isolation by high-intensity focused ultrasound: first-in-man study with a steerable balloon catheter
Heart Rhythm
(2007) - et al.
Lethal atrioesophageal fistula after pulmonary vein isolation using high-intensity focused ultrasound
Heart Rhythm
(2008) - et al.
Atrial fibrillation ablation: reaching the mainstream
Pacing Clin Electrophysiol
(2006) - et al.
Worldwide survey on the methods, efficacy and safety of catheter ablation for human atrial fibrillation
Circulation
(2005) - et al.
Spontaneous initiation of atrial fibrillation by ectopic beats originating in the pulmonary veins
N Engl J Med
(1998) - et al.
Pulmonary vein stenosis after catheter ablation of atrial fibrillation
Circulation
(1998) - et al.
Electrophysiological breakthroughs from the left atrium to the pulmonary veins
Circulation
(2000)
Circumferential pulmonary-vein ablation for chronic atrial fibrillation
N Engl J Med
Circumferential radiofrequency ablation of pulmonary vein ostia: a new anatomic approach for curing atrial fibrillation
Circulation
Catheter ablation for paroxysmal atrial fibrillation: segmental pulmonary vein ostial ablation versus left atrial ablation
Circulation
Venice Chart International consensus document on atrial fibrillation ablation
J Cardiovasc Electrophysiol
Multi-electrode catheters using low energy phased radiofrequency for ablation of chronic atrial fibrillation
Europace
Safety using novel multi-array catheters and phased radiofrequency energy in left atrial ablation for persistent atrial fibrillation
Heart Rhythm
Cited by (0)
Dr. Boersma is a stockholder with Ablation Frontiers Inc. Dr. Wijffels has received grant support for research from Ablation Frontiers, Inc. Dr. Oral is a stockholder and a consultant of Ablation Frontiers, Inc. Dr. Morady is a stockholder and a consultant of Ablation Frontiers, Inc.